Gouws Capital LLC’s AbbVie ABBV Stock Holding History

Gouws Capital LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$679K	Sell	2,700 -135	-5%	-$29K	0.32%	33
2026 Q1	$617K	Sell	2,835 -20	-0.7%	-$4.44K	0.33%	34
2025 Q4	$652K	Hold	2,855	–	–	0.34%	33
2025 Q3	$661K	Hold	2,855	–	–	0.36%	33
2025 Q2	$530K	Buy	2,855 +440	+18%	+$81.8K	0.29%	34
2025 Q1	$506K	Buy	2,415 +60	+3%	+$11.7K	0.3%	34
2024 Q4	$418K	Hold	2,355	–	–	0.29%	32
2024 Q3	$465K	Hold	2,355	–	–	0.31%	32
2024 Q2	$404K	Buy	2,355 +125	+6%	+$20.7K	0.29%	31
2024 Q1	$406K	Hold	2,230	–	–	0.31%	31
2023 Q4	$346K	Sell	2,230 -1,125	-34%	-$164K	0.28%	34
2023 Q3	$500K	Hold	3,355	–	–	0.42%	33
2023 Q2	$452K	Buy	3,355 +175	+6%	+$25.7K	0.37%	34
2023 Q1	$507K	Buy	3,180 +320	+11%	+$48.9K	0.45%	33
2022 Q4	$462K	Sell	2,860 -640	-18%	-$98.1K	0.44%	34
2022 Q3	$470K	Sell	3,500 -215	-6%	-$30.9K	0.47%	33
2022 Q2	$569K	Hold	3,715	–	–	0.54%	32
2022 Q1	$602K	Sell	3,715 -15	-0.4%	-$2.18K	0.49%	33
2021 Q4	$505K	Buy	+3,730	New	+$441K	0.41%	37

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gouws Capital LLC's ABBV Position: Q2 2026 in Review

Gouws Capital LLC reduced its AbbVie (ABBV) stake by 4.8% in Q2 2026, selling an estimated $29K and leaving 2,700 shares worth $679K. The position accounts for 0.32% of the portfolio, ranked #33.

Gouws Capital LLC first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Gouws Capital LLC held 2,700 shares of AbbVie worth $679K as of Q2 2026.
Gouws Capital LLC sold 135 AbbVie shares in Q2 2026, an estimated $29K.
AbbVie made up 0.32% of Gouws Capital LLC's portfolio in Q2 2026, its #33 holding.
Gouws Capital LLC first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gouws Capital LLC's 13F filing for Q2 2026, filed 13 Jul 2026.